Insider buying last 90 days
No open-market insider purchases were filed for BIIB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BIIB insider filing, plotted on the chart in Gekko.Open BIIB in Gekko
NASDAQ: BIIB
Biogen (BIIB) Stock Analysis & Forecast
$215.50−3.55 (−1.6%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryBiogen (BIIB) closes at $215.50, down 1.6%, holding above both its 50-day average of $210.56 and 200-day average of $192.84. The GekkoIndex reads 56.4, placing the stock in the Neutral zone. Against Gekko Fair Value of $332.14, the current price sits 35.1% below that level, a gap that bears watching. Over the past year the stock has returned 48.8%, with a six-month gain of 17.5%, and shares trade near their 52-week high of $225.80.
This week's coverage centers on clinical and analyst activity. Biogen reported positive Phase 3 VALIANT adolescent subgroup results for EMPAVELI, showing a 75% relative reduction in proteinuria in patients aged 12-17 compared to placebo. Separately, Wolfe Research upgraded Biogen to Outperform alongside AbbVie, assigning a $300 price target and citing late-stage pipeline programs and strategic M&A. Other coverage noted a consensus price target of $230.14 and comparisons with peers Mesoblast and Fulcrum Therapeutics, alongside a modest increase in institutional holdings by Corient Private Wealth LP.
Looking ahead, Biogen's next earnings report is scheduled for 28 October 2026, before the open, 38 days away and outside a typical 20-trading-day window. In the last eight quarters the company has beaten EPS estimates each time, with the most recent print showing $3.60 versus a $3.04 estimate. Seasonality over the next 20 trading days has averaged a 3.9% return across 5 years, rising in 3 of them. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, while analyst coverage from 28 firms shows 18 buy ratings and a consensus target of $237.19.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $215.50200-day averageGekko Fair Value $332.14
Key stats
- Market cap
- $31.84B
- P/E ratio
- 38.6
- Forward P/E
- 13.3
- EPS, TTM
- $5.60
- Revenue, TTM
- $10.03B
- Profit margin
- 8.3%
- Dividend yield
- —
- Beta
- 0.17
- Volume
- 2.63M avg 802,994
- 1-year return
- +48.8%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5.2%
- 50-day average
- $210.56
- 200-day average
- $192.84
- Next earnings
- Oct 28 before open
- Shares outstanding
- 147.8M
Biogen swing-trade checklist
Biogen scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $215.50 is above the 50-day ($210.56) and 200-day ($192.84) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
56.4, Neutral
Reading 56.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
35.1% below
Price is 35.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 38 days
Next report Oct 28, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.9% on average
From this point in the calendar, the next 20 trading days averaged +3.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Biogen stock chart and price history
Biogen closed at $215.50 on Sep 18, 2026, +48.8% over the past year, inside a 52-week range of $135.39 to $225.80.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.7%
- 3 months
- +9.6%
- 6 months
- +17.5%
- 1 year
- +48.8%
The full BIIB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BIIB in Gekko
Follow Biogen through every session
Put BIIB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BIIB in GekkoFree for 7 days. No credit card required.
About Biogen
Biogen works in medicine for the brain and nervous system, focused on discovering, developing and manufacturing treatments for neurological and neurodegenerative disease. It is best known for its multiple sclerosis medicines, among them TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA, alongside OCREVUS for relapsing and primary progressive MS and ADUHELM for Alzheimer's disease.
Beyond neurology, the company sells SPINRAZA for spinal muscular atrophy and FUMADERM for plaque psoriasis, along with cancer and immune therapies such as RITUXAN, RITUXAN HYCELA and GAZYVA, used against lymphoma, leukemia, rheumatoid arthritis and related conditions. It also produces biosimilar versions of established biologics, including BENEPALI, IMRALDI and FLIXABI. Its pipeline spans investigational compounds for MS, Alzheimer's and dementia, neuromuscular and movement disorders, psychiatric conditions, immunology, acute neurological events and neuropathic pain, together with additional biosimilars in development.
Biogen trades on the NASDAQ under the ticker BIIB.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- biogen.com
Biogen GekkoIndex: the smart money zone
Biogen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.4, in the Neutral zone, down 0.5 points over five sessions.
56.4Neutral
Down 0.5 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 66 | +0.2% | −1.9% | ||
| Accumulation | 214 | −0.5% | −1.2% | ||
| Neutral (current zone) | 355 | +0.3% | +1.2% | ||
| Distribution | 25 | −0.1% | −2.0% | ||
| Selling | 2 | Too few readings yet | |||
Average BIIB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BIIB price, zone by zone.Track BIIB in Gekko
Is Biogen stock overvalued? Gekko Fair Value
Biogen trades 35.1% below Gekko Fair Value of $332.14, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Biogen shares are worth, recalculated every trading day.
$332.14
Gekko Fair Value, Sep 17, 2026
35.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BIIB in Gekko
Biogen insider and Congress trading
No open-market insider purchases were filed for Biogen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BIIB were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BIIB, plotted on the chart in Gekko.Open BIIB in Gekko
Buybacks
Biogen has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2022
- $250.0M
- As a share of market cap
- 0.79%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BIIB.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Biogen earnings: next date and track record
Biogen reports on Oct 28, 2026, before the open (38 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected before the open, 38 days away
- EPS estimate
- $2.03
- Revenue estimate
- $2.64B
8 of 8reports beat the EPS estimate
±3.2%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Biogen reported a strong Q2 2026 driven by its growth portfolio, which surpassed its legacy MS franchise. Key commercial highlights included faster-than-expected conversion to SPINRAZA high-dose across major markets, strong uptake of recently acquired Apellis assets (SYFOVRE and Empaveli), and approval/rollout of LEQEMBI IQLIK enabling subcutaneous/home dosing. Management emphasized a diversified late-stage pipeline with near-term catalysts (SLE TOPAZ readouts in Q4, TRANSCEND and AMR/MVI data in 2027, and multiple other registrational programs). The company reiterated focus on prioritizing programs (e.g., BIIB091 BTK paused for strategic evaluation), advancing novel neuroscience assets (BIIB080/dirinersen), and pursuing tissue-delivery approaches like brain shuttles. Financially, core pharmaceutical revenue was $1.8B (up 4% y/y, 12% q/q) with the growth portfolio >$1B (up 24% y/y). Management discussed commercial execution, market access considerations (Part D, medical exceptions), and R&D prioritization, while remaining measured on risk and regulatory paths.
- Risks flagged
- Clinical trial risk (heterogeneity, high placebo responses in SLE), regulatory uncertainty (approvals and labeling), payer and market access challenges (Part D coverage, prior authorizations, medical exceptions), competitive dynamics in crowded markets (RRMS/BTK inhibitors, A-beta/anti-tau combinations), development prioritization/portfolio allocation, and potential delays/pauses in specific programs (e.g., delayed graft function paused).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $3.60 est $3.04 | $2.74B est $2.46B | +1.1% |
| Apr 29, 2026 | $3.57 est $2.89 | $2.48B est $2.29B | +3.2% |
| Feb 6, 2026 | $1.99 est $1.63 | $2.28B est $2.20B | +4.6% |
| Oct 30, 2025 | $4.81 est $3.88 | $2.45B est $2.34B | +4.3% |
| Jul 31, 2025 | $5.47 est $3.90 | $2.65B est $2.33B | +4.2% |
| May 1, 2025 | $3.02 est $2.90 | $2.43B est $2.23B | +2.0% |
| Feb 12, 2025 | $3.44 est $3.36 | $2.45B est $2.41B | −0.7% |
| Oct 30, 2024 | $4.08 est $3.79 | $2.47B est $2.43B | −5.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Biogen stock forecast and analyst price targets
Analysts’ average 12-month price target for Biogen is $237.19, +10.1% from the last close, from 28 firms rating the stock in the last 90 days.
$237.19consensus 12-month target, +10.1% from the last close
Now $215.50Avg $237.19
Low $175High $300
Each firm’s latest rating in the last 90 days: 28 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Wells Fargo | $250 | +16.0% |
| Sep 10 | HSBC | $175 | −18.8% |
| Sep 9 | BMO Capital | — | — |
| Sep 3 | Piper Sandler | $245 | +13.7% |
| Aug 25 | RBC Capital | $260 | +20.6% |
+1.2%average 20-day move after past Neutral readings
+3.9%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Biogen seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Biogen averaged +3.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.6% | 1 of 5 |
| Next 10 trading days | +5.0% | 2 of 5 |
| Next 15 trading days | +3.4% | 3 of 5 |
| Next 20 trading days | +3.9% | 3 of 5 |
| Next 30 trading days | +3.8% | 2 of 5 |
For scale, BIIB’s typical 20-trading-day move in either direction is about 5.2%.
Biogen market cap and key statistics
Biogen’s market cap is $31.84B, with a P/E ratio of 38.6 and revenue of $10.03B over the last twelve months.
Valuation
- Market cap
- $31.84B
- P/E ratio
- 38.6
- Forward P/E
- 13.3
- EPS, TTM
- $5.60
- Gekko Fair Value
- $332.14
Trading
- Volume
- 2.63M
- Avg volume, 20 days
- 802,994
- 52-week high
- $225.80
- 52-week low
- $135.39
- Shares outstanding
- 147.8M
Financials
- Revenue, TTM
- $10.03B
- Profit margin
- 8.3%
- Return on equity
- 4.6%
- Quarterly earnings growth, YoY
- −84.8%
Risk and income
- Beta
- 0.17
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5.2%
Biogen stock news this week
Coverage of Biogen this week reads positive: 6 positive, 2 neutral and 1 negative headlines.
- Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head ContrastDefense World, Sep 18
- BIIB Looks 11.6% Overvalued on GF Value™GuruFocus, Sep 17
- Biogen reports trial results for kidney disease drug in adolescentsInvesting.com, Sep 17
- Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIBDefense World, Sep 17
- Reviewing Fulcrum Therapeutics (NASDAQ:FULC) & Biogen (NASDAQ:BIIB)Defense World, Sep 17
- Biogen to Report Third Quarter 2026 Financial Results October 28, 2026Biogen, Sep 15
Biogen peers
Biogen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
A peer links to its own page where one exists.
Biogen stock FAQ
What is Biogen’s market cap?
Biogen’s market cap is $31.84B at the Sep 18, 2026 close of $215.50, with 147.8M shares outstanding. The shares trade on a P/E ratio of 38.6.
What is the Biogen stock forecast?
The consensus analyst 12-month price target for Biogen is $237.19, +10.1% from the last close. Of the 28 firms that rated the stock in the last 90 days, 18 rate it a buy, 9 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Biogen stock overvalued or undervalued?
On Gekko’s estimate Biogen is undervalued: the Sep 18, 2026 close of $215.50 is 35.1% below Gekko Fair Value of $332.14. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Biogen report earnings next?
Biogen is expected to report on Oct 28, 2026, before the market opens (38 days away). Analysts expect earnings of $2.03 per share on revenue of $2.64B. Biogen beat the earnings estimate in 8 of its last 8 reports, moving 3.2% on average across the report.
What is Biogen’s 52-week high and low?
Biogen’s 52-week high is $225.80 and its 52-week low is $135.39; it closed at $215.50 on Sep 18, 2026, +48.8% over the past year.
Is Biogen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Biogen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.